Fidelity BioPharma Co. – Trademark Portfolio
Entity Type: 03
Fidelity BioPharma Co. holds 22 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 21 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 5 trademarks are registered and 12 are pending. Notable registered marks include ANHOA, ONTRALFY, CRENEUROS, and WHERE INNOVATION MATTERS FPB. The owner is based in NEW HAVEN, CT.
157 CHURCH STREET, SUITE 1915
NEW HAVEN, CT 06510
Showing of trademarks Trademarks
Trademark Classifications
Fidelity BioPharma Co.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Fidelity BioPharma Co. have?
Fidelity BioPharma Co. has 22 U.S. trademarks filed with the USPTO. Of these, 5 registered, 12 pending, 5 abandoned.
What trademark classes does Fidelity BioPharma Co. file in?
Fidelity BioPharma Co. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Fidelity BioPharma Co.'s most well-known trademarks?
Fidelity BioPharma Co.'s registered trademark portfolio includes well-known marks such as ANHOA, ONTRALFY, CRENEUROS, and WHERE INNOVATION MATTERS FPB. These are among 5 currently registered trademarks in the portfolio.
What is Fidelity BioPharma Co.'s trademark registration success rate?
Fidelity BioPharma Co. has a 50% trademark registration rate, with 5 out of 10 resolved applications resulting in successful registration. Currently, 12 applications are pending review.